Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab
Nulla a velit quis ex ornare rhoncus. Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris.…
Read more
Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
Nulla a velit quis ex ornare rhoncus. Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris.…
JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma
Nulla a velit quis ex ornare rhoncus. Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris.…
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab
Nulla a velit quis ex ornare rhoncus. Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris.…
TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer
Former Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE) ROCKVILLE, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) –…
Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement
Donec imperdiet risus justo, vel malesuada erat fermentum at. Morbi at laoreet mauris.